BioMarin Pharmaceutical Inc. develops and commercializes medicines for rare genetic diseases, with recurring news centered on commercial portfolio performance, regulatory approvals, clinical data and business development. Company updates commonly reference therapies for achondroplasia, phenylketonuria, hemophilia, mucopolysaccharidosis and lysosomal storage diseases, including VOXZOGO, PALYNZIQ, GALAFOLD and POMBILITI + OPFOLDA.
BioMarin news also covers financial results, guidance, acquisition integration, debt financing and governance changes. Clinical and regulatory announcements focus on genetically defined conditions, skeletal disorders, enzyme-based therapies and investigational rare-disease programs such as DMX-200 for focal segmental glomerulosclerosis.
BioMarin (Nasdaq: BMRN) completed its acquisition of Amicus Therapeutics on April 27, 2026, in an all-cash deal at $14.50 per share, valuing the transaction at approximately $4.8 billion. The deal adds commercial therapies Galafold (migalastat) and Pombiliti + Opfolda, plus U.S. rights to Phase 3 candidate DMX-200. BioMarin plans to provide updated FY 2026 guidance on its Q1 earnings call on May 4, 2026.
BioMarin (NASDAQ: BMRN) will host a conference call and webcast on Monday, May 4, 2026 at 4:30 p.m. ET to discuss first quarter 2026 financial results and provide a general business update. Alexander Hardy, president and CEO, will host the call.
Dial-in and replay numbers are provided and a live audio webcast and one-week replay will be available via the investor site: https://investors.biomarin.com/.
BioMarin (Nasdaq: BMRN) announced a Board leadership transition: Ian T. Clark was elected Chair, subject to his election at the Annual Meeting on June 2, 2026, and will succeed Richard A. Meier, who is retiring after two decades on the Board.
Mr. Clark joined the Board in 2025 and brings executive and board experience including prior service as Genentech CEO; the change becomes effective immediately following the Annual Meeting.
BioMarin (Nasdaq: BMRN) reported new data showing early treatment with VOXZOGO (vosoritide) improves proportionality, arm span and BMI in children with achondroplasia, with durable multi-year gains. Key findings include a 4.7 cm additional height gain after four years and ULBR improvement to −0.53 by year four. Real-world data cover >5,000 infants and children across 50+ countries and align with clinical-trial results supporting earlier treatment.
BioMarin (Nasdaq: BMRN) announced FDA approval of PALYNZIQ (pegvaliase-pqpz) for adolescents aged 12 and older with phenylketonuria (PKU).
Approval is based on Phase 3 PEGASUS data: mean blood Phe fell from 1025 to 567 µmol/L at Week 72 on PALYNZIQ versus 1029 to 973 µmol/L on diet alone, with a treatment difference of -409 µmol/L (95% CI -579, -240). Common adverse reactions (≥20%) included injection site reactions, arthralgia, headache and hypersensitivity reactions.
BioMarin (NASDAQ: BMRN) announced management will participate in four investor conferences in March 2026: TD Cowen (Mar 4), Leerink (Mar 9), Jefferies Biotech on the Bay (Mar 10) and Barclays Global Healthcare (Mar 11).
Executives will take part in fireside chats, 1x1 meetings, and live webcasts; replay will be available for a limited time.
BioMarin (NASDAQ: BMRN) reported full-year 2025 total revenues of $3.22B, up 13% year-over-year, and fourth-quarter revenues of $875M, up 17% YoY. VOXZOGO revenue rose 26% in 2025 to $927M; Enzyme Therapies grew 9% to $2.105B.
The company announced a definitive agreement to acquire Amicus, expects close in Q2'26, and provided 2026 guidance excluding Amicus: total revenues $3.325–3.425B and Non-GAAP diluted EPS $4.95–5.15. BioMarin voluntarily withdrew ROCTAVIAN, taking ~ $240M charges in Q4'25.
Phenylketonuria market (includes BioMarin - BMRN) is forecast to expand through 2034 driven by rising diagnosis rates, expanded newborn screening, and multiple emerging therapies.
Key datapoints: US had 18,800 diagnosed PKU cases in 2024; sepiapterin received regulatory approvals in 2025 and pegvaliase sBLA entered FDA review.
BioMarin (NASDAQ: BMRN) will host a conference call and webcast on Monday, February 23, 2026 at 4:30 p.m. ET to discuss fourth-quarter and full-year 2025 financial results and provide a business update.
Alexander Hardy, President and CEO, will lead the call. Dial-in numbers, replay details, and a live webcast are available via the company's investor website; a replay will be archived for one week.
BioMarin (NASDAQ: BMRN) closed a private offering of $850 million 5.500% senior unsecured notes due 2034 at 100% issue price to help fund its pending acquisition of Amicus.
The company plans to combine the Notes, a $2.0 billion Term Loan B, a $800 million Term Loan A, a proposed $600 million revolver and cash to pay acquisition consideration, fees and related borrowings.
Proceeds were placed in escrow; mandatory redemption triggers apply if the acquisition is not completed by December 19, 2026.